Overview

A Pilot Study Evaluating -hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing -hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Tao Zhang

Treatments:

Capecitabine
Oxaliplatin